{"id":1990,"date":"2024-01-12T09:30:00","date_gmt":"2024-01-12T09:30:00","guid":{"rendered":"https:\/\/www.sedapds.com\/?p=1990"},"modified":"2024-01-17T11:14:44","modified_gmt":"2024-01-17T11:14:44","slug":"seda-announces-establishment-of-gmp-manufacturing-capability","status":"publish","type":"post","link":"https:\/\/www.sedapds.com\/news\/seda-announces-establishment-of-gmp-manufacturing-capability\/","title":{"rendered":"Seda announces establishment of GMP manufacturing capability"},"content":{"rendered":"

Seda Pharma Development Services Ltd are delighted to announce the expansion of their capabilities into clinical phase, GMP manufacturing. Construction of a state-of-the-art GMP manufacturing facility and associated laboratories within a recently acquired 50,000 sqft building (The Lakehouse) is ongoing. This is adjacent to, and will complement, Seda\u2019s existing development laboratory and office complex on Cheadle Royal Business Park.<\/span>\u00a0<\/span><\/p>\n

\u00a0<\/span>An \u00a38M investment package is supporting the build of 5 manufacturing suites for early-stage clinical trials. The facility will have capability for the manufacture and packing of a range of oral dosage forms including tablets, capsules, powders & liquids and enabled formulations such as spray-dried amorphous solid dispersions, semi-solid lipidic products etc.\u00a0<\/span>\u00a0<\/span><\/p>\n

This initial investment will utilise only part of the building footprint allowing future investment and expansion of GMP services in line with emerging innovative technologies and changing Client project requirements.<\/span>\u00a0<\/span><\/p>\n

Dr Paul Stott<\/a><\/span>, Seda CEO, commented:\u00a0<\/span>\u00a0<\/span><\/p>\n

\u201c<\/span>Seda was originally formed to address a market need for integrated pharmaceutical development and clinical pharmacology services, particularly in the development of challenging molecules. Our consistent year on year growth has been underpinned by our ability to evolve our service offering in response to client needs. Establishing a GMP manufacturing capability is the natural next step to give our clients an end to end service of the highest scientific and quality standards.<\/span><\/i>\u201d<\/span>\u00a0<\/span><\/p>\n

The investment was supported, in part, via non-dilutive funding from Santander UK plc<\/a>.<\/span>\u00a0<\/span><\/p>\n

Paul Stott said of Seda\u2019s relationship with Santander \u201c<\/span>Having solid financial backing from Santander has supported our rapid expansion without a loss of control. This allows us to maintain our laser focus on delivering long term client value and exceptional product quality without the distraction of having to meet short term investor demands<\/span><\/i>.\u201d<\/span>\u00a0<\/span><\/p>\n

Debbie Worthington, Relationship Director, Corporate & Commercial Banking, Santander UK said:<\/span> \u201c<\/span><\/em><\/span>Santander UK is well equipped to provide specialist support to companies in the pharmaceutical and medical sectors and <\/span>we\u2019re<\/span> delighted to see a company in this industry, that has banked with us since <\/span>inception<\/span>, grow so rapidly and have such an exciting future ahead. Seda is making a significant and positive contribution to medical science internationally and as its banking partner, we are pleased to be able to support this next phase of their growth with the expansion of their capabilities into clinical phase, GMP<\/span> (good manufacturing practice) manufacturing<\/span><\/span>.\u2019\u2019<\/span><\/span><\/em><\/p>\n

MHRA approval is anticipated in Q3 2024 with GMP production slots available thereafter.<\/span>\u00a0<\/span><\/p>\n

When fully operational Seda anticipate the facility will support an additional 100 high-value and high-skilled roles and we are actively seeking out the best talent to build the team<\/a>.<\/span>\u00a0<\/span><\/p>\n

For more information please contact Paula Goddard<\/a><\/p>\n